The German research group which has generated important parts of Follicum’s research data on human skin will present their results both as a poster and in an oral presentation at the World Congress for Hair Research. The congress takes place in Miami in Florida, USA, on 18-21 November 2015. To read the full press release […]
As previously communicated, Follicum’s intention is to start a clinical phase I/IIa study around year-end 2015/early 2016. We can now announce that a cooperation with the Clinical Research Center for Hair and Skin Science (“CRC”) in Berlin, Germany, has been initiated regarding our planned clinical phase I/IIa study. Follicum’s intention is to submit an application […]
Follicum announced in March 2015 that they had started two larger toxicity studies to add information to the two short time toxicity studies and continue development. The short time studies were finalized in February 2015, and showed no adverse effects. The two larger toxicity studies have now been finished according to plan, showing very promising […]
Follicum announce today that the synthesis of the peptide has been completed. The peptide is the active ingredient of the product planned to be used in the clinical Phase I/IIa study. Production of product for the clinical Phase I/IIa study Follicum announced in early June that the company had signed an agreement with the peptide […]
Follicum’s half-year report 2015 (1 January to 30 June) is now published. Click here to open the report (in Swedish).
Follicum announce today that a joint cooperation agreement has been signed with PolyPeptide Group and Recipharm AB in anticipation of the clinical trials which are estimated to start in the beginning of 2016. Read more here.
Follicum’s financial report for the first quarter 2015 (1 January to 31 March) is now published. Click here to open the report (in Swedish).
Follicum announces that they have had a successful scientific advisory meeting with BfArM – the Federal Institute for Drugs and Medical Devices in Germany. BfArM did not have any major questions or objections to the material that Follicum presented, which indicates that, given nothing unpredicted occurs in the tox studies, Follicum may start a clinical […]
Yesterday, 29 April 2015, Follicum AB held their Annual General Meeting. The meeting resolved to adopt the presented income statement and balance sheet as well as to dispose of the company’s profit according to the Board’s proposal in the Annual Report. Furthermore, the meeting decided that no dividend will be paid for fiscal year 2014. […]
Follicum’s Annual Report for the financial year 2014 is now published in Swedish on the company’s website (Swedish version). It is also available in Follicum’s office at Scheelevägen 22, Lund. For more information please contact: Dr Jan Alenfall, CEO Follicum AB Tel +46 46 19 21 97 Email firstname.lastname@example.org